Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
Status:
Withdrawn
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a non-inferiority, open label, randomized trial of women on buprenorphine Medication
Assisted Therapy for opioid use disorder in pregnancy.Patients will be randomized to either
the long acting monthly subcutaneous SublocadeTM or to short acting sublingual Suboxone®.
Phase:
Phase 4
Details
Lead Sponsor:
Ohio State University
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination